spacer
home > ict > autumn 2016 > what is the risk?
PUBLICATIONS
International Clinical Trials

What Is The Risk?

Access to high-quality, real time data is the driver behind risk-based monitoring (RBM) – a methodology used to enhance subject safety and data quality, and to deliver significant efficiency benefits. An RBM approach replaces the in-person, 100% source data verification (SDV) process based on the identification of risks and issues. Its use in clinical trials is increasing as sponsors begin to realise the potential to improve the quality of data while, at the same time, reducing total trial costs by an estimated15-20% (1). This approach is also in line with the push from regulatory authorities in the US and EU for targeted monitoring, as it is more effective than spreading resources equally across all sites.

However, managing and analysing all clinical data during the study – to identify potential current issues and future risks – is a complex speciality, which becomes particularly challenging in global, multi-site trials. Large pharmaceutical companies and CROs may have entire departments devoted to this, but that kind of scope and expertise is expensive and, for many small- and midsized biopharmaceutical and device organisations developing a product on a budget, it simply may not be an option.

Aligning these smaller teams with affordable and robust technologies, which enable the adoption of a risk-based approach to study monitoring, creates cost efficiencies that can significantly benefit them without compromising data value or patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Greg Ambra is Vice President of Clinical Operations at DZS Clinical Services. With nearly 20 years of experience in the clinical research industry, he has held strategic leadership positions in various sponsor and CRO companies. Greg has led DZS Clinical Services since 2012, and earned his Master’s degree in Medical Sciences from Boston University, US.

As Senior Director of Biostatistics, Jean Battikha has worked in the pharma industry as a statistician for nearly 40 years. He has been involved in the design, analysis and reporting of many clinical trials across several therapeutic areas, as well as with many NDA submissions in both the US and EU.
spacer
Greg Ambra
spacer
spacer
spacer
Jean Battikha
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

New offices at leading science hub support the Company’s rapid growth following recent investment New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

SCOPE Europe – Summit for Clinical Ops Executives Europe

17-18 September 2019, Barcelona, Spain

Building on the success of its long-running US-based counterpart, Summit for Clinical Trials Operations Executives Europe (SCOPE Europe) is a two-day event serving clinical innovation leaders, clin ops execs, functional heads, category managers, and those responsible for the planning and management of clinical trials in Europe and the Rest of the World. The event will feature opening and closing plenary keynote sessions, five conference tracks, interactive breakout discussion groups, and networking. It is an opportunity for leaders from large, mid-sized, and small pharma, specialty pharma, biotech, vendor companies, and academic research centers to come together to share best practices and discuss the new era of analytics-driven and patient-centric trials.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement